198 related articles for article (PubMed ID: 29662494)
1. Evolution of Neutralization Response in HIV-1 Subtype C-Infected Individuals Exhibiting Broad Cross-Clade Neutralization of HIV-1 Strains.
Cheedarla N; Hemalatha B; Anangi B; Muthuramalingam K; Selvachithiram M; Sathyamurthi P; Kailasam N; Varadarajan R; Swaminathan S; Tripathy SP; Vaniambadi SK; Vadakkupattu DR; Hanna LE
Front Immunol; 2018; 9():618. PubMed ID: 29662494
[TBL] [Abstract][Full Text] [Related]
2. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
4. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
[TBL] [Abstract][Full Text] [Related]
5. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
6. Viral Characteristics Associated with Maintenance of Elite Neutralizing Activity in Chronically HIV-1 Clade C-Infected Monozygotic Pediatric Twins.
Mishra N; Makhdoomi MA; Sharma S; Kumar S; Dobhal A; Kumar D; Chawla H; Singh R; Kanga U; Das BK; Lodha R; Kabra SK; Luthra K
J Virol; 2019 Sep; 93(17):. PubMed ID: 31217240
[TBL] [Abstract][Full Text] [Related]
7. Cross Type Neutralizing Antibodies Detected in a Unique HIV-2 Infected Individual From India.
Vidyavijayan KK; Cheedarala N; Babu H; Precilla LK; Sathyamurthi P; Chandrasekaran P; Murugavel KG; Swaminathan S; Tripathy SP; Hanna LE
Front Immunol; 2018; 9():2841. PubMed ID: 30619250
[No Abstract] [Full Text] [Related]
8. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
9. Emergence of broadly neutralizing antibodies and viral coevolution in two subjects during the early stages of infection with human immunodeficiency virus type 1.
Sather DN; Carbonetti S; Malherbe DC; Pissani F; Stuart AB; Hessell AJ; Gray MD; Mikell I; Kalams SA; Haigwood NL; Stamatatos L
J Virol; 2014 Nov; 88(22):12968-81. PubMed ID: 25122781
[TBL] [Abstract][Full Text] [Related]
10. Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals.
Cheedarla N; Precilla KL; Babu H; Vijayan KKV; Ashokkumar M; Chandrasekaran P; Kailasam N; Sundaramurthi JC; Swaminathan S; Buddolla V; Vaniambadi SK; Ramanathan VD; Hanna LE
Sci Rep; 2017 Apr; 7():46557. PubMed ID: 28436427
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of broadly cross-reactive neutralizing antibodies in patients infected with HIV-1 B'/C recombinant (CRF07_BC).
Bao MJ; Geng WQ; Cui HL; Zhang XL; Xu DB; Nian H; Dai D; Wang YN; Shang H
Mol Med Rep; 2012 May; 5(5):1311-7. PubMed ID: 22344547
[TBL] [Abstract][Full Text] [Related]
12. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.
Landais E; Huang X; Havenar-Daughton C; Murrell B; Price MA; Wickramasinghe L; Ramos A; Bian CB; Simek M; Allen S; Karita E; Kilembe W; Lakhi S; Inambao M; Kamali A; Sanders EJ; Anzala O; Edward V; Bekker LG; Tang J; Gilmour J; Kosakovsky-Pond SL; Phung P; Wrin T; Crotty S; Godzik A; Poignard P
PLoS Pathog; 2016 Jan; 12(1):e1005369. PubMed ID: 26766578
[TBL] [Abstract][Full Text] [Related]
13. High prevalence of neutralizing activity against multiple unrelated human immunodeficiency virus type 1 (HIV-1) subtype B variants in sera from HIV-1 subtype B-infected individuals: evidence for subtype-specific rather than strain-specific neutralizing activity.
van Gils MJ; Edo-Matas D; Schweighardt B; Wrin T; Schuitemaker H
J Gen Virol; 2010 Jan; 91(Pt 1):250-8. PubMed ID: 19793903
[TBL] [Abstract][Full Text] [Related]
14. Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India.
Hussain SI; Panneerselvam N; Solomon S; Solomon SS; Adam K; Chandrasekaran E; Montefiori DC; Pachamuthu B
J Int Assoc Provid AIDS Care; 2017; 16(2):201-208. PubMed ID: 23422744
[TBL] [Abstract][Full Text] [Related]
15. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
[TBL] [Abstract][Full Text] [Related]
16. Profiles of neutralizing antibody response in chronically human immunodeficiency virus type 1 clade B'-infected former plasma donors from China naive to antiretroviral therapy.
Hu X; Hong K; Zhao C; Zheng Y; Ma L; Ruan Y; Gao H; Greene K; Sarzotti-Kelsoe M; Montefiori DC; Shao Y
J Gen Virol; 2012 Oct; 93(Pt 10):2267-2278. PubMed ID: 22791603
[TBL] [Abstract][Full Text] [Related]
17. Mapping of Neutralizing Antibody Epitopes on the Envelope of Viruses Obtained from Plasma Samples Exhibiting Broad Cross-Clade Neutralization Potential Against HIV-1.
Cheedarla N; Sundaramurthi JC; Hemalatha B; Anangi B; Nesakumar M; Ashokkumar M; Vidya Vijayan KK; Tripathy SP; Swaminathan S; Vaniambadi SK; Ramanathan DV; Hanna LE
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):169-184. PubMed ID: 30328700
[TBL] [Abstract][Full Text] [Related]
18. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1).
Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA
Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912
[TBL] [Abstract][Full Text] [Related]
19. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
González N; McKee K; Lynch RM; Georgiev IS; Jimenez L; Grau E; Yuste E; Kwong PD; Mascola JR; Alcamí J
PLoS One; 2018; 13(3):e0193773. PubMed ID: 29558468
[TBL] [Abstract][Full Text] [Related]
20. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
